Recent Company News

• 05:40 PM ET Jul 01, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:58 AM ET Jul 01, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:19 AM ET Jul 01, 2025
  

  StreetAccount Summary - US Pre-market trading

• 07:06 AM ET Jul 01, 2025
  

  Adagene announces up to $25M strategic investment from Sanofi ($1.95, 0.00)

• 05:07 PM ET May 30, 2025
  

  Adagene enters ADS sales agreement for up to $100M with Leerink - 424B5 ($1.94, 0.00)

• 05:08 PM ET May 22, 2025
  

  Adagene announces presentation of updated data from phase 1B/2 study of Muzastotug (ADG126) in combination with KEYTRUDA ($1.63, 0.00)

• 04:40 PM ET May 09, 2025
  

  Adagene files $200M mixed shelf; enters into sales agreement for up to $100M of ADSs with Leerink Partners - F-3 ($1.60, 0.00)

• 08:04 AM ET Mar 24, 2025
  

  Adagene reports Q4 EPS ($0.35) vs FactSet ($0.33) [1 est] ($1.69, 0.00)

• 08:02 AM ET Feb 27, 2025
  

  Adagene announces investigator initiated phase 2 trial for Neoadjuvant Muzastotug (ADG126) in colorectal cancer ($1.98, 0.00)

• 06:42 AM ET Jan 31, 2025
  

  Adagene downgraded to equal-weight from overweight at Morgan Stanley ($1.85, 0.00)